logo
Plus   Neg
Share
Email

GSK Says ViiV Healthcare Gets CRL From FDA For Cabotegravir And Rilpivirine

GlaxoSmithKline plc (GSK.L,GSK) announced Monday that its majority-owned ViiV Healthcare, with Pfizer Inc. and Shionogi Limited as shareholders, received a complete response letter or CRL from the US Food and Drug Administration. The CRL is for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV-1 infection in virologically suppressed adults.

The company said the reasons given in the CRL relate to Chemistry Manufacturing and Controls or CMC. There have been no reported safety issues related to CMC and there is no change to the safety profile of the products used in clinical trials to date.

Cabotegravir is an integrase strand transfer inhibitor developed by ViiV Healthcare. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor developed by Janssen Sciences Ireland UC.

GlaxoSmithKline noted that ViiV Healthcare will work closely with the FDA to determine the appropriate next steps for this New Drug Application.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The NextGen Consortium announced the launch of reusable cup pilots in local cafes in the City of San Francisco and City of Palo Alto, California. The local cafes have joined the Consortium's efforts to advance reusable, recyclable and/or compostable cup solutions in select pilots. NextGen Consortium is a multi-year consortium that addresses single-use food packaging waste globally. DISH Network Corp. (DISH) Wednesday reported a profit for the fourth-quarter that increased about 15 percent from last year, but quarterly revenue decreased 2 percent. Both earnings per share and revenue top analysts' estimates. Net Pay-TV subscribers for the quarter decreased by about 194,000 from the prior quarter. Advanced Bionics LLC, the US unit of Swiss hearing aid maker Sonova Holding AG, has recalled certain un-implanted cochlear implant devices due to decreased hearing performance. The recall would incur costs in the range of 40 million Swiss francs to 50 million francs. In a statement, Sonova said that...
Follow RTT
>